Pay in 4 interest-free payments of $6.82 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
Back to Journals Diabetes, Metabolic Syndrome and Obesity Volume 18 Relative Effectiveness and Safety of the GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists, Semaglutide and Liraglutide in the Treatment of Obese Type 2 Diabetics: A Prospective Observational Cohort Study in Poland Authors Hoffmann K, Michalak M , Paczkowska A Received 1 April 2025 Accepted for publication 1 July 2025 Published 7 August 2025 Volume 2025:18 Pages 27232738 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 3 Editor who approved publication: Dr Halis Akturk Karolina Hoffmann, 1 Micha Michalak, 2 Anna Paczkowska 3 1 Department and Clinic of Internal Diseases and Metabolic Disorders, Poznan University of Medical Sciences, Pozna, Poland
However, it should be approached with care and only under expert guidance
The compound's effects on insulin sensitivity make it particularly relevant for obese individuals at risk for type 2 diabetes or those with existing metabolic syndrome
However, being prepared by informing the test administrator, providing proof of your prescription, and understanding your rights can help prevent any unnecessary stress or confusion
Clinical studies show that patients using GLP-1 medications can experience a weight loss of 1015% or more of their total body weight
Establish a licensing scheme for highrisk aesthetic procedures Launch a ministerial Task Force to coordinate regulation and enforcement Extend existing underage aesthetics legislation across Scotland, Wales, and Northern Ireland Enforce swift removal of unsafe injectable products sold online
US$ 29.94
US$ 27.52
US$ 26.84
US$ 29.43
US$ 23.62
US$ 21.08
